Viewing StudyNCT02941926



Ignite Creation Date: 2024-05-06 @ 9:16 AM
Last Modification Date: 2024-10-26 @ 12:12 PM
Study NCT ID: NCT02941926
Status: COMPLETED
Last Update Posted: 2023-10-24
First Post: 2016-10-20

Brief Title: Study to Assess the Safety and Efficacy of Ribociclib LEE011 in Combination With Letrozole for the Treatment of Men and PrePostmenopausal Women With HR HER2- aBC
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Breast Cancer
Keywords:
Name View
HR-positive HER2-negative View
advanced breast cancer View
LEE011 View
ribociclib View
letrozole View
goserelin View
CDK View
CDK4 View
CDK6 View
CDK46 View
Phase IIIb View
ER-positive View
PR-positive View
premenopausal View
postmenopausal View
men with advanced breast cancer View